Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04417231
Other study ID # P-05 CASTRO1
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 28, 2021
Est. completion date December 31, 2022

Study information

Verified date January 2023
Source Pentracor GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke. The term therapeutic apheresis commonly refers to medical procedures, where pathogenic constituents are being removed from the circulating blood. Elimination is performed by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood (circulation) to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient. The adsorber "PentraSorb® CRP" used for CRP apheresis is CE-certified. It is designated to the selective depletion of C-reactive protein from human blood.


Description:

The purpose of the study is to evaluate the safety and efficacy of CRP apheresis in patients following ischemic stroke. CRP apheresis is to be conducted with the aim of reducing cerebral damage following the guideline-appropriate primary therapy of ischemic stroke. A possible protective effect of CRP apheresis will be assessed by clinical scores, laboratory determination of immunologic parameters and determination of the size of the infarct area by magnetic resonance imaging (MRI). The study will be randomized, controlled and monocentric.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ischaemic stroke with determination of infarct size by imaging (MRI) - NIHSS 1-24 - CRP increase = 5 mg/l within presumed 72 hours after stroke and/or CRP value > 10 mg/l - written informed consent of the patient or his legal representative Exclusion Criteria: - age < 18 years - Severe dysphagia (danger of aspiration pneumonia) - Clinical or laboratory evidence of a severe systemic infection - Participation in other interventional studies - Contraindications against apheresis therapy - Modified Rankin Scale (mRS) before index event = 3 - Intracranial hemorrhage - Epileptic seizure in the context of the acute event - Pregnancy, lactation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CRP apheresis
Selective CRP apheresis by use of the "PentraSorb"-CRP

Locations

Country Name City State
Germany Abteilung für Neurologie, Universität Ulm Ulm Bayern

Sponsors (1)

Lead Sponsor Collaborator
Pentracor GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of CRP apheresis Incidence of expected and unexpected adverse effects 24 hours after each apheresis
Secondary Stroke Severity National Institute of Health Stroke Scale (NIHSS) score - ranging from 0-42 - higher values represent a worse outcome before first apheresis and 6 ± 3 days after infarction and 12 ± 2 weeks after infarction
Secondary Functional Outcome Modified ranking scale (mRS) score - ranging from 0-6 with higher scores signifying worse outcome before first apheresis and 6 ± 3 days after infarction and 12 ± 2 weeks after infarction
Secondary Dependency Barthel Index (BI) - ranging from 0-100 with higher scores signifying better outcome 6 ± 3 days after infarction and 12 ± 2 weeks after infarction
Secondary Infarct size Infarct growth measured via diffusion-weighted imaging (DWI)-FLAIR volume change 6 ± 3 days after infarction and 12 ± 2 weeks after infarction
Secondary Concentration of inflammatory biomarkers (CRP, IL-6, SAA) CRP, Interleukin-6, and serum amyloid A are determined twice daily until discharge of the patient (for a maximum of 7 days). 0-7 days after infarction
See also
  Status Clinical Trial Phase
Recruiting NCT03993236 - Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke Phase 4
Completed NCT04069767 - Innovative Physiotherapy in Stroke Rehabilitation N/A
Recruiting NCT06342206 - The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Enrolling by invitation NCT04956211 - Periodontal Treatment and Ischemic Stroke N/A
Active, not recruiting NCT05098236 - Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage N/A
Completed NCT03942588 - High-intensity Interval Training After Stroke N/A
Recruiting NCT04949334 - Effects of Respiratory Muscle Training in Patients With Acute Ischemic Stroke N/A
Terminated NCT04095767 - Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke N/A
Not yet recruiting NCT06352086 - Understanding Visual Processing After Occipital Stroke
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Completed NCT01937182 - The Efficacy of Citalopram Treatment in Acute Stroke Phase 2
Completed NCT03649295 - Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke N/A
Recruiting NCT05303649 - Effects of Neuronavigated Theta Burst Stimulation in Therapy of Post-stroke Aphasia N/A
Completed NCT04233515 - Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County
Completed NCT05102877 - Sensory Versus Motor Level Neuromuscular Electrical Stimulation N/A
Completed NCT04089917 - A Study of the Use of the Q Aspiration Catheter to Remove Clot in Stroke Patients
Completed NCT05221112 - Effects of PNF Patterns Training on Trunk Balance, and Gait in Chronic Stroke Patients N/A
Not yet recruiting NCT05035953 - Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke Phase 2
Completed NCT06326801 - Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients N/A